Quest Diagnostics Hits New 52-Week High of $239.90, Up 66.78%

Quest Diagnostics, Inc. has reached a significant milestone by hitting a new 52-week high of USD 239.90 on July 28, 2026. This achievement underscores the company's robust performance in the market, particularly as it has demonstrated a remarkable 66.78% increase over the past year, significantly outpacing the S&P 500's 16.26% gain during the same period. With a market capitalization of USD 31,451 million, Quest Diagnostics operates within the miscellaneous industry and is classified as a mid-cap company. The stock's price-to-earnings (P/E) ratio stands at 28.00, reflecting its valuation in relation to earnings. Additionally, the company boasts a strong dividend yield of 29.40%, indicating a commitment to returning value to shareholders. Financial metrics reveal a solid return on equity of 15.54% and a manageable debt-to-equity ratio of 0.75, suggesting effective management of financial resources. The latest quarterly results highlighted impressive operating cash flow of USD 1,678 million and net sales reaching USD 2,761 million, further solidifying Quest Diagnostics' position in the market.